Table 1.

Antitumor effects of sunitinib in patients with advanced RCC without prior nephrectomy

Pt no.Diameter baseline (cm)RECIST
Volume
PFS (mo)Survival (mo)
Primary (%)Metastases (%)Overall (%)OverallTumor baseline (cm3)Tumor Δ (%)Necrosis* baseline (cm3)Necrosis* Δ (%)Solid Δ (%)
113−31−34−33PR695−64131−43−6818+18+
27−12−27−21SD138−5161−13−8145
36−6−27−15SD131−2414195−501120+
413−16−14−15SD536−2718939−6334
5700SD189−1828109−4015+15+
6a11−19−9−22SD773−5812434−7513+13+
6b5−33−9−22SD49−603359−87
77−17−42−35PR133−31517−5456
88185SD227124−1413712
915−18−56−32PR1715−4664229−901015
108−11−45−32PR281−38208−43−241415+
1110107741PD4395327139770.24
129−20−100−29SD293−3045129−591014+
136−8−55−20SD116−37225−471314+
146−2−32−27SD158−4222245−889+9+
1577−16−10SD174142853768+
1616−12−28−17SD1651−25228158−5412+12+
175115018SD57816163−5214
  • Abbreviations: RECIST primary, RECIST applied for primary tumor only; RECIST metastases, RECIST applied for metastases only; RECIST overall, overall RECIST applied for both primary tumor and metastases; PR, partial response; SD, stable disease; PD, progressive disease; Volume tumor, total volume of primary tumor; Volume necrosis, volume necrotic part of the primary tumor; Volume solid, volume solid part of the primary tumor; Δ (%), change in percentage; PFS, progression-free survival.

  • * The hypodense nonenhancing part of the tumor is referred to as necrosis.

  • Metastases were present but not measurable.

  • Patient no. 6 had bilateral primary tumors in situ.